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lipoprotein (LDL) clearance from plasma through degradation of low-density lipoprotein receptors (LDL-R).
Mutations that up- or down-regulate PCSK9 have been shown to affect risk of cardiovascular disease
independently of plasma LDL level. In light of these discoveries, plasma PCSK9 level may prove useful as a
biomarker for cardiovascular risk.
Methods: An exhaustive search of the available medical literature was performed using the MEDLINE
(Ovid), CINAHL and Web of Science databases. Keywords included PCSK9, evolocumab, alirocumab,
myocardial infarction, cardiovascular disease and coronary artery disease (CAD). Inclusion criteria consisted
of studies published in English that were performed on a human population, in the absence of statin therapy
with endpoints including occurrence of a first cardiovascular event and severity of coronary artery stenosis.
Results: Two studies met eligibility criteria for this systematic review. One was a cross-sectional study and the
other was a nested case-control study. The first study was performed on two separate cohorts, with the first
cohort of 771 patients showing no correlation between serum PCSK9 level and coronary artery disease
(CAD), and the second cohort of 822 patients showing a positive correlation. Both cohorts showed a positive
correlation between elevated serum PCSK9 level and acute MI but not prior MI. The second study of 716
women showed no correlation between serum PCSK9 level and risk for future cardiovascular event. Both
studies had very low quality of evidence as judged by the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) guideline.
Conclusion: The two studies failed to reach a consensus on whether PCSK9 can be useful as a biomarker for
cardiovascular risk; however, transiently elevated serum PCSK9 levels occurred with acute MI. Future studies
could be performed to further evaluate the potential use of PCSK9 as a cardiovascular biomarker, as well as a
diagnostic marker for myocardial infarction (MI).
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Abstract   
 
Background: Proprotein convertase subtilisin/kexin 9 (PCSK9) is a protein that prevents low-
density lipoprotein (LDL) clearance from plasma through degradation of low-density lipoprotein 
receptors (LDL-R).  Mutations that up- or down-regulate PCSK9 have been shown to affect risk 
of cardiovascular disease independently of plasma LDL level.  In light of these discoveries, 
plasma PCSK9 level may prove useful as a biomarker for cardiovascular risk.  
 
Methods:  An exhaustive search of the available medical literature was performed using the 
MEDLINE (Ovid), CINAHL and Web of Science databases.  Keywords included PCSK9, 
evolocumab, alirocumab, myocardial infarction, cardiovascular disease and coronary artery 
disease (CAD). Inclusion criteria consisted of studies published in English that were performed 
on a human population, in the absence of statin therapy with endpoints including occurrence of a 
first cardiovascular event and severity of coronary artery stenosis.   
 
Results:  Two studies met eligibility criteria for this systematic review.  One was a cross-
sectional study and the other was a nested case-control study.  The first study was performed on 
two separate cohorts, with the first cohort of 771 patients showing no correlation between serum 
PCSK9 level and coronary artery disease (CAD), and the second cohort of 822 patients showing 
a positive correlation.  Both cohorts showed a positive correlation between elevated serum 
PCSK9 level and acute MI but not prior MI.  The second study of 716 women showed no 
correlation between serum PCSK9 level and risk for future cardiovascular event.  Both studies 
had very low quality of evidence as judged by the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) guideline.  
 
Conclusion:  The two studies failed to reach a consensus on whether PCSK9 can be useful as a 
biomarker for cardiovascular risk; however, transiently elevated serum PCSK9 levels occurred 
with acute MI.  Future studies could be performed to further evaluate the potential use of PCSK9 
as a cardiovascular biomarker, as well as a diagnostic marker for myocardial infarction (MI). 
 
Keywords:  PCSK9, Evolocumab, Alirocumab, Myocardial Infarction, Cardiovascular Disease  
and Coronary Artery Disease 
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PCSK9 as a Biomarker for Cardiovascular Risk 
BACKGROUND 
 Proprotein convertase subtilisin/kexin 9 (PCSK9) is a protein that opposes the regulation 
of plasma low-density lipoprotein (LDL) levels through degradation of LDL receptors (LDL-R).  
Because of this fact, PCSK9 has recently become a promising target for therapy aimed at 
reducing plasma LDL levels and, hence, cardiovascular risk in patients. 1 Monoclonal antibodies 
against PCSK9, also called PCSK9 inhibitors, have demonstrated effectiveness in lowering LDL 
levels when taken either as monotherapy 2 or in addition to traditional statin therapy, 3 but have 
not yet completed trials to demonstrate effective improvement of cardiovascular outcomes.  
Plasma LDL levels are an important biomarker for cardiovascular risk in patients, and 
cardiovascular disease is the leading cause of death in both men and women in the United States, 
resulting in 610 000 mortalities annually, or 1 in 4 deaths. 4  
 Interestingly, mutations of PCSK9 have shown greater influence on cardiovascular risk 
than would be expected from their accompanied LDL level.  Gain-of-function mutations in 
PCSK9 have been found to cause familial hypercholesterolemia and are associated with 
premature coronary heart disease. 5 PCSK9 loss-of-function mutations can reduce LDL levels 
and are associated with protection against coronary heart disease.  In fact, multiple studies 6-8 
have shown that loss of PCSK9 function reduces risk of cardiovascular disease to a magnitude 
much greater than the LDL reduction alone would predict. 
 As an independent biomarker for cardiovascular disease, PCSK9 may be useful.  This 
idea has been investigated before, 9 but due to the confounding effect of statins to raise serum 
PCSK9 levels 10 in those studies, further investigation in patients not on statin therapy is 
 8 
necessary.  The fact that most patients with cardiovascular risk are on chronic statin therapy 
makes this type of study difficult.  This systematic review examines the current evidence for 
PCSK9 as a biomarker for cardiovascular risk in patients not on statin therapy.     
METHODS 
 An exhaustive search of the literature was performed using the MEDLINE (Ovid), 
CINAHL, and Web of Science databases.  Keywords included PCSK9, evolocumab, alirocumab, 
myocardial infarction, cardiovascular disease and coronary artery disease (CAD).  Article titles 
and abstracts were used to determine inclusion/exclusion.  Inclusion criteria consisted of studies 
published in English that were performed on a human population, in the absence of statin therapy 
with endpoints including subsequent occurrence of a first cardiovascular event and severity of 
coronary artery stenosis.  Articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) guidelines. 11 
RESULTS 
 The initial search of MEDLINE using Ovid yielded 371 results, with 369 excluded that 
did not meet inclusion criteria.  An identical search of CINAHL showed 30 results, with 1 
relevant duplicate from Ovid.  Twenty-nine results did not meet inclusion criteria.  A final search 
of Web of Science yielded 382 results, with 1 duplicate from Ovid.  The other 381 results did not 
meet inclusion criteria.  Of the 2 included articles, one is a cross-sectional study design 12 and 
one is a case control design. 13 See Table I. 
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Almontashiri et al 
 This study 12 measured serum PCSK9 levels at time of angiography for 1593 adults in 
two separate cross-sectional studies: the Ottawa Heart Genomics Study (OHGS) and the Emory 
Cardiology Biobank (EmCB) study.   
In the OHGS, a total of 3918 patients were enrolled. There were 3147 patients who were 
taking statins, so this review will focus on the 771 patients who were not on statin therapy.  
These patients were sorted into a case (492 patients) and a control (279 patients) group based on 
presence of significant coronary artery stenosis of greater than 50% for the cases and 
insignificant stenosis of less than 30% for the controls.  Patients with intermediate stenosis 
between 30-50% were excluded.  Patients with previous diagnosis of diabetes mellitus were also 
excluded. 12  
OHGS showed no significant difference in serum PCSK9 levels between cases and 
controls in patients not taking statin therapy.  Cases had an average serum PCSK9 level of 309.0 
+/- 99.7 ng/mL while serum PCSK9 level, on average, for controls, was 317.1 +/- 131.9 ng/mL 
(p = 0.376). 12 
Elevated serum PCSK9 levels in OHGS were associated with acute myocardial 
infarction, but not with prior incidence of MI.  Of patients not taking statins in OHGS, 94 had an 
MI, with 45 experiencing an acute MI and 49 having experienced a prior MI.  Average serum 
PCSK9 level was 363.5 +/- 140.0 ng/mL for patients experiencing acute MI compared to 302.0 
+/- 91.3 ng/mL for 398 cases without MI (p = 0.004).  Serum PCSK9 levels were, on average, 
315.9 +/- 107.5 ng/mL for patients with prior MI (p = 0.977). 12 See Table II. 
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In the EmCB study, a total of 2357 patients were enrolled, of which 822 plasma samples 
were taken for this study.  Patients were excluded if they were on statin therapy or had a prior 
diagnosis of diabetes mellitus.  These patients were sorted in a similar fashion to the OHGS 
study, with 465 cases showing greater than 50% stenosis of a coronary artery and 357 controls 
showing less than 20% stenosis.  Patients with stenosis between 20-50% were excluded. 12  
In contrast to OHGS, EmCB showed a significant association between serum PCSK9 
levels and coronary artery stenosis.  Average serum PCSK9 level for cases was 385.0 +/- 146.9 
ng/mL, while the average level for controls was 340.4 +/- 125.2 ng/mL (p < 0.001). 12  
Elevated serum PCSK9 levels were associated with acute MI in EmCB, but, like OHGS, 
there was no association with prior MI.  Acute MI occurred in 74 patients, with an average 
PCSK9 serum level of 445.0 +/- 171.7 ng/mL.  This is compared to 273 patients who did not 
experience acute or prior MI and had an average serum PCSK9 level of 369.9 +/- 139.1 ng/mL 
(p = 0.0037).  There were 118 patients who experienced a prior MI, and they had an average 
PCSK9 level of 382.3 +/- 139.1 ng/mL (p = 0.0954). 12 See Table II. 
Ridker et al 
 This nested case control study 13 measured baseline serum PCSK9 levels in 716 women 
from a total prospective cohort of 28 263 women in the Women’s Health Study (WHS).  The 
cohort was initially free of reported cardiovascular disease and patients were subsequently 
followed for an average of 17 years to evaluate occurrence of cardiovascular events, including 
MI, stroke or death from coronary heart disease.  There were 358 cases, consisting of patients 
who experienced a cardiovascular event during follow-up, and 358 matched controls who did not 
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experience a cardiovascular event.  Patients were excluded from this study if they were on statin 
therapy. 13  
 Elevated serum PCSK9 levels were not shown to correlate with subsequent occurrence of 
cardiovascular events in the Ridker et al study.  The average serum PCSK9 level for cases was 
304.4 ng/mL (252.9-365.9) compared to an average of 299.7 (252.9-358.8) for the controls (p = 
0.94). 13 See Table III. 
DISCUSSION 
 The results from the reviewed studies are unclear as to whether serum PCSK9 levels 
correlate with future cardiovascular risk in patients.  The authors of the two studies 12,13 cited in 
this review support a lack of correlation; however, this picture is not entirely clear. Almontashiri 
et al 12 found no association between serum PCSK9 level and coronary atherosclerosis in patients 
not taking statin therapy in OHGS, but did find correlation in patients not taking statin therapy in 
EmCB.  Ridker et al 13 found no correlation between plasma PCSK9 level in women not taking 
statins and risk of future cardiovascular events.  The very low quality of the evidence presented 
herein necessitates further study to ascertain an accurate picture of the role of PCSK9 as a 
cardiovascular biomarker.  
 The discrepancy between analogous findings in the OHGS and EmCB by Almontashiri et 
al 12 may be explained by the inclusion of controls with aortic valve disease and minimal 
coronary artery stenosis in OHGS 14, due to the unknown relationship between aortic valve 
disease and serum PCSK9 levels.  The authors put forward an additional possibility that the 
correlation found between serum PCSK9 level and CAD incidence in EmCB was caused by the 
differential control criteria between OHGS and EmCB, with controls having less than 30% 
 12 
coronary stenosis in OHGS and less than 20% stenosis in EmCB. 12 This theory seems 
paradoxical, however, because it uses a correlation between PCSK9 level and CAD to explain 
away a correlation between PCSK9 and CAD, and is therefore unlikely.       
  The finding of plasma PCSK9 level elevation with acute MI is of note in the study by 
Almontashiri et al. 12 Though plasma PCSK9 level was elevated with acute MI, it was found to 
have no elevation associated with prior MI, pointing to the probability of transient PCSK9 
elevation with MI. Further investigation into the cause of this transient elevation may help 
explain why PCSK9 mutations appear to affect coronary heart disease risk independently of LDL 
level.  
The possibility that PCSK9 functions as an acute phase reactant in acute MI was 
suggested by Almontashiri et al 12 as an explanation for its’ transient elevation in acute MI.  A 
study 15 is cited as finding that serum PCSK9 levels are not elevated acutely in severe trauma, 
however, which points away from this hypothesis.  
 Another interesting theory proposed by the authors was that PCSK9 elevation may 
transiently occur prior to acute MI. 12 PCSK9 has been shown to bind to LDL-R related protein 8 
(LRP8), 16 which may promote platelet aggregation 17 in patients.  Serum PCSK9 levels, 
incidence of acute coronary events and platelet aggregation are all highest in the morning, 18-20 
providing support for this idea.  
Transient elevation of serum PCSK9 level with MI suggests that further study may be 
done to evaluate PCSK9 as a clinical diagnostic marker for acute MI, as well as pharmaceutical 
PCSK9 inhibition for management of acute MI.  The completion of further studies evaluating 
 13 
long-term cardiovascular outcomes with PCSK9 inhibitors will guide future treatment guidelines 
for this therapy and possibly help clarify the role PCSK9 plays in cardiovascular disease. 
The study by Ridker et al 13 was performed on a cohort completely composed of women. 
This is a drawback, because the majority of cardiovascular deaths in the United States occur in 
men. 4 
Future research should be directed at cohorts composed of both men and women who are 
not being treated with statin therapy in order to accurately determine whether PCSK9 can be 
used as a biomarker for future cardiovascular risk, or to help in the diagnosis of acute MI.   
Until further research can fully assess its’ value, it appears that the use of PCSK9 as a 
biomarker for cardiovascular risk is limited.     
CONCLUSION 
 Although two studies performed on patients in the absence of statin therapy have failed to 
reach a concrete consensus as to whether elevated plasma PCSK9 levels correlate with future 
cardiovascular risk, serum PCSK9 level showed a correlation with acute MI and not with prior 
MI, indicating a transient elevation with MI occurrence.  Further investigation in cohorts 
consisting of men and women not currently being treated with statin therapy will be necessary to 
evaluate whether PCSK9 can be used as a biomarker for cardiovascular risk or as a diagnostic 
marker for acute MI.  
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Table I. Characteristics of Reviewed Studies 
 
Study Design Downgrade Criteria Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision Publication Bias 
Almontashiri 
et al1 
Cross-
Sectional 
Not Serious Not Serious Seriousa Not Serious Unlikely NA Very Low 
Ridker et al2 Case-Control Not Serious Seriousb Not Serious Not Serious Unlikely NA Very Low 
a Serum PCSK9 level was not predictive of CAD in OHGS, but was predictive of CAD in EmCB 
b Serum PCSK9 levels in WHS were only collected on women 
Table II. Summary of Findings from Almontashiri et al 12 
 
Authors Study 
Design 
Cohort Group Number of 
Patients 
Age (Years) Male Sex, 
N (%) 
PCSK9 
(ng/mL) 
p-value 
Almontashiri 
et al 
Cross-
Sectional 
OHGS Cases 492 65 +/- 11 334 (67.9) 309.0 +/- 99.7 0.376 
Controls 279 63 +/- 12 132 (47.3) 317.1 +/- 131.9 
EmCB Cases 465 65 +/- 12 352 (75.7) 385.0 +/- 146.9 0.000003 
Controls 357 56 +/- 12 193 (54.1) 340.4 +/- 125.2 
 
Table III. Summary of Findings from Ridker et al 13 
 
Authors Study Design Cohort Group Number of 
Patients 
Age (Years) PCSK9 (ng/mL) p-value 
Ridker et al Case-Control WHS Cases 358 63 +/- 5 304.4 (252.9-365.9) 0.94 
Control 358 63 +/- 5 299.7 (252.9-358.8) 
 
